1	Alzheimer's Disease cerebrospinal fluid Biomarkers and kidney function in normal and
2	cognitively impaired older adults.
3	Ihab Hajjar, MD ^{1,2,3} Reem Neal, MD ¹ ; Zhiyi Yang, PhD ² , James J. Lah, MD, PhD ² ;
4	
5	¹ Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
6	² Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA.
7	³ Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
8	
9	Word count: 1985
10	
11	Category: Original Investigation
12	
13	Corresponding Author: Ihab Hajjar, MD, Department of Neurology, University of Texas Southwestern
14	Medical Center, Dallas, TX 75390-8806, USA.
15	Email: Ihab.Hajjar@UTSouthwestern.edu Tel: 214/645-9533

16

Page | 1

17 KEY POINTS:

- 18 Question: Are Cerebrospinal Fluid (CSF)AD-biomarker measurements impacted by kidney function?
- 19 Findings: In this analysis of data from 973 individuals who had both cerebrospinal fluid (CSF) AD-
- 20 biomarkers (Aβ42, Tau, and pTau181) and kidney function measurements, there were significant
- 21 associations between estimated glomerular filtration rate (eGFR) and measures of CSF AD-biomarkers.
- 22 These associations were more pronounced in those with cognitive impairment.
- 23 Meaning: Kidney function may have a significant impact on AD-biomarker measurements in the CSF,
- especially in those in the early symptomatic stages of AD.

Importance: Recent Alzheimer's disease (AD) clinical trials have used Cerebrospinal fluid (CSF)

26 Abstract:

28 biomarker levels for screening and enrollment. Preliminary evidence suggests Alzheimer's Disease (AD) 29 risk may be related to impaired renal function but the association of variation in levels of commonly used 30 AD biomarkers with kidney function are unknown. 31 **Objective:** To investigate the association between estimated glomerular filtration rate (eGFR), CSF levels 32 of AD biomarkers: amyloid beta1–42 (A β 42), Tau or phosphorylated Tau181 (pTau). 33 Design, Setting, and Participants: We conducted an analysis using data from participants enrolled in 34 two research protocols at the Goizueta Alzheimer's Disease Research Center that had simultaneous 35 measurements of serum creatinine at the time of their Cerebrospinal fluid (CSF) collection (N=973). The participants had a mean age of 66.52 years, 23.33% were African American, and 63% were women, with 36 37 42.46% having mild cognitive impairment (MCI). The estimated glomerular filtration rate (eGFR) was 38 obtained from chronic kidney disease Epidemiology Collaboration. All participants had similar CSF 39 collection procedures. AB42, Tau or pTau were measured on the Luminex ALZBIO platform. General linear models and individual data were used to assess relationships between biomarkers and eGFR. 40 41 **Results:** Lower eGFR was associated with lower A β 42/Tau ratio (slope= 0.033 units, p<0.0001) and 42 Aβ42 (slope=0.75, p=0.002) and higher Tau (slope= -0.39, p<0.0001) and pTau (slope= -0.13, p=0.0002). Although these associations remained significant after adjusting for cognitive status, we observed 43 44 interactions between MCI and eGFR. This interaction revealed that the impact of eGFR on AD biomarker 45 levels was more robust in individuals with cognitive impairment (interaction MCI*GFR p-values were 0.005 for Ab42, 0.04 for tau and pTau, and 0.05 for the ratio). 46 47 **Conclusion:** We found a significant association between eGFR with CSF AD-biomarkers that may differ 48 by cognitive status. This suggests that kidney function should be considered both in the context of 49 interpreting AD biomarkers as well as exploring potential systemic factors that may increase risk of AD.

- 50 Future longitudinal studies need to further explore the impact of kidney function on the pathogenesis of
- 51 AD and related Biomarkers.

53 Introduction:

Alzheimer's Disease (AD) biomarkers such as amyloid beta1-42 (A β 42), Tau, phosphorylated tau (pTau), 54 and more specifically the A β 42/Tau ratio play a crucial role in the diagnosis of Alzheimer's Disease.¹ 55 56 These biomarkers are also commonly used in clinical trials for screening and enrollment and the use of a combination of these biomarkers has been found to yield improved case identifications.²⁻⁵ The variation in 57 levels of these AD biomarkers by demographics and comorbidities is still being explored with recent 58 evidence suggesting that consideration of these variations is important.⁶⁻⁸ Kidney function may impact 59 levels of disease markers, especially on plasma protein-based markers.⁹ Whether there is a similar impact 60 61 on AD-biomarkers commonly measured in cerebrospinal fluid (CSF) remains unclear. Preliminary evidence has suggested that impaired kidney function is associated with cognitive impairment based on 62 neuropsychological assessments.¹⁰⁻¹² A recent analysis of the Whitehall II prospective study suggested a 63 64 connection between a lower estimated glomerular filtration rate (eGFR) and the risk of clinical dementia diagnosis.¹³ It has also been suggested that the risk of Alzheimer's disease is related to impaired renal 65 function and its impact on levels of AD biomarkers in the plasma.^{14,15} Since the CSF is a highly controlled 66 67 microenvironment, studying the association of kidney function with CSF biomarkers offers great insight into the kidney-brain axis. ^{12,16} 68

69 In this study, we aimed to investigate the association between estimated glomerular filtration rate (eGFR), 70 as a measure of kidney function, and the levels of AD biomarkers in the CSF—specifically, the $A\beta 42/Tau$ ratio and individual other individual AD biomarkers: Amyloid beta 1-42 (Aβ42), Tau, and phosphorylated 71 72 Tau181 (pTau)—in individuals with and without cognitive impairment. By analyzing the data from 73 participants enrolled in two research protocols, we sought to determine whether eGFR is associated with 74 alterations in the levels of AD biomarkers in the CSF. we also explored potential interactions between 75 kidney function, AD biomarker levels, and mild cognitive impairment (MCI) – a common precursor to 76 AD, which might provide critical insights into the impact of renal health on cognitive decline especially 77 in individuals in the early symptomatic stages of AD.

78 Methods:

79 We analyzed data from participants in studies conducted within the Goizueta Alzheimer's Disease 80 Research Center (ADRC; N= 973, mean age=66.5, 52% mild cognitive impairment (MCI), 31% AA, 62% 81 women) who had simultaneous measurement of their serum creatinine during their visit for CSF 82 collection. Participants were enrolled in two observational protocols that were approved by the Emory 83 IRB (Institutional Review Board) and each participant signed a written informed consent. All participants 84 underwent identical lumbar puncture procedures, CSF analysis, and kidney function measurements: 85 Brain Stress Hypertension and Aging program (B-SHARP: n= 375 and ADRC Clinical Research in 86 Neurology (CRIN): n=598). B-SHARP sample participants were identified either through a referral from 87 the Goizueta ADRC or through strategic community partnerships with grass-roots health education 88 organizations, health fairs, advertisements, and mail-out announcements. An appropriate study informant, 89 defined as an individual who has regular contact with the participant for at least once a week (in person or 90 by telephone), was also identified. The potential study participants attended a screening visit, during 91 which they underwent cognitive testing. A study physician performed a clinical evaluation and lumbar 92 punctures (LP). CRIN is an ADRC-affiliated research protocol that is offered to individuals undergoing lumbar puncture as part of their evaluation at the Emory Cognitive Neurology clinic. LP procedures and 93 94 preanalytical protocols are identical in all our ADRC-affiliated research and clinical protocols. 95 Demographics (age, sex, race, education), anthropometrics (weight and height), medical diagnosis, and 96 income levels were collected at baseline by interview. Following a fast of no less than 6 hours, CSF 97 samples were collected via lumbar puncture using 24G Sprotte atraumatic spinal needles. Samples were 98 collected in sterile polypropylene tubes, separated into 0.5cc aliquots, and stored at -80 °C. CSF 99 Biomarkers, A β 1-42, tau, and Ptau181, were measured using the multiplex xMAP Luminex platform 100 (Luminex Corp, Austin, TX) with Innogenetics (INNO-BIA AlzBio3; Ghent, Belgium; for research useonly reagents) immunoassay kit-based reagents. Estimated GFR was calculated using the Chronic 101 Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.¹⁷ CKD-EPI is the most widely used 102

103	method to calculate eGFR which is calculated using this equation: $41 \times min (Scr/\kappa, 1)\alpha \times max (Scr/\kappa, 1)$ -
104	1.209×0.993 Age $\times 1.018$ [if female] $\times 1.159$ [if African American] (where Scr is serum creatinine in
105	μ mol/L, κ is 61.9 for females and 79.6 for males, α is -0.329 for females and -0.411 for males, min
106	indicates the minimum of Scr/ κ or 1, and max indicates the maximum of Scr/ κ or 1).
107	Statistical analysis: Statistical analysis was performed with SAS statistical software version 9.4 M6. The
108	statistical significance was defined as $p < 0.05$. Although the 2 protocols had identical procedures for the
109	biomarkers and kidney function, we conducted an individual participant data metanalysis with a General
110	linear model and "protocol" as the random effect to assess relationships between biomarkers and eGFR
111	using the combined data. ¹⁸ In addition to the eGFR/biomarker measurement analysis, we conducted an
112	interaction analysis to assess if the associations differed by cognitive status.
113	Results:
114	Participant Characteristics:
114 115	Participant Characteristics: The Study's sample included 973 participants, consisting of 613 women (63%) and 360 men (37%). The
114 115 116	Participant Characteristics: The Study's sample included 973 participants, consisting of 613 women (63%) and 360 men (37%). The mean age was 66.52 (SD: 8.83). The participant distribution included 227 African American patients
114 115 116 117	Participant Characteristics: The Study's sample included 973 participants, consisting of 613 women (63%) and 360 men (37%). The mean age was 66.52 (SD: 8.83). The participant distribution included 227 African American patients (23.33%) and 746 Caucasian patients (76.67%). Among the participants, 413 patients (42.45%) were
114 115 116 117 118	Participant Characteristics: The Study's sample included 973 participants, consisting of 613 women (63%) and 360 men (37%). The mean age was 66.52 (SD: 8.83). The participant distribution included 227 African American patients (23.33%) and 746 Caucasian patients (76.67%). Among the participants, 413 patients (42.45%) were diagnosed with Mild Cognitive Impairment (MCI). The mean eGFR was 78 (standard deviation: 16.70)
114 115 116 117 118 119	Participant Characteristics: The Study's sample included 973 participants, consisting of 613 women (63%) and 360 men (37%). The mean age was 66.52 (SD: 8.83). The participant distribution included 227 African American patients (23.33%) and 746 Caucasian patients (76.67%). Among the participants, 413 patients (42.45%) were diagnosed with Mild Cognitive Impairment (MCI). The mean eGFR was 78 (standard deviation: 16.70) mL/min/1.73 m ² with no significant difference between participants with Normal Cognition (NC) or
114 115 116 117 118 119 120	Participant Characteristics: The Study's sample included 973 participants, consisting of 613 women (63%) and 360 men (37%). The mean age was 66.52 (SD: 8.83). The participant distribution included 227 African American patients (23.33%) and 746 Caucasian patients (76.67%). Among the participants, 413 patients (42.45%) were diagnosed with Mild Cognitive Impairment (MCI). The mean eGFR was 78 (standard deviation: 16.70) mL/min/1.73 m ² with no significant difference between participants with Normal Cognition (NC) or participants with Mild Cognitive Impairment (MCI). As expected, we found that individuals within the
114 115 116 117 118 119 120 121	Participant Characteristics: The Study's sample included 973 participants, consisting of 613 women (63%) and 360 men (37%). The mean age was 66.52 (SD: 8.83). The participant distribution included 227 African American patients (23.33%) and 746 Caucasian patients (76.67%). Among the participants, 413 patients (42.45%) were diagnosed with Mild Cognitive Impairment (MCI). The mean eGFR was 78 (standard deviation: 16.70) mL/min/1.73 m ² with no significant difference between participants with Normal Cognition (NC) or participants with Mild Cognitive Impairment (MCI). As expected, we found that individuals within the MCI group exhibited a substantially lower average Aβ42 level, and higher average Tau and pTau levels.
114 115 116 117 118 119 120 121 122	Participant Characteristics:The Study's sample included 973 participants, consisting of 613 women (63%) and 360 men (37%). The mean age was 66.52 (SD: 8.83). The participant distribution included 227 African American patients (23.33%) and 746 Caucasian patients (76.67%). Among the participants, 413 patients (42.45%) were diagnosed with Mild Cognitive Impairment (MCI). The mean eGFR was 78 (standard deviation: 16.70) mL/min/1.73 m² with no significant difference between participants with Normal Cognition (NC) or participants with Mild Cognitive Impairment (MCI). As expected, we found that individuals within the MCI group exhibited a substantially lower average Aβ42 level, and higher average Tau and pTau levels. The key characteristics of the study participants are provided in Table 1.

124 Association of eGFR with CSF AD-biomarkers in Full sample:

125	We observed a significant association between eGFR and the A β 42/Tau ratio (0.033, p<0.0001). We also
126	found significant associations between eGFR and all three CSF AD-biomarkers: A β 42 (slope per unit
127	increase: 0.75, p=0.002), Tau (-0.39, p<0.0001), and pTau (-0.13, p=0.0002). The results show that for
128	every unit increase in eGFR, there is a corresponding change in CSF AD-biomarkers as follows: an
129	increase in both the A β 42/Tau ratio, and A β 42 and a decrease in both Tau, and pTau. (Table 2)
130	Furthermore, our analysis showed that each unit increase in eGFR corresponded to an approximate
131	increase of 0.52 in A β 42 levels, however, for Tau and pTau, we found that each unit increase in eGFR
132	corresponded with a decrease in Tau and pTau levels in the CSF, even after adjusting for MCI status.
133	(Table 2) Further, individuals within the MCI group exhibited a substantially lower average $A\beta 42$ level
134	measuring approximately (-88.88 pg/ml), lower Aβ42/Tau ratio (-2.85), and higher levels of Tau
135	(40.51pg/ml), and pTau (17.03 pg/ml) after adjusting for eGFR. (Table S.2)
136	
137	The impact of MCI on the association between CSF AD-biomarkers and eGFR:
138	Our subsequent analysis aimed to explore the potential interaction among CSF AD biomarkers, eGFR,
139	and MCI. We found a notable difference in the variation of CSF AD biomarkers with eGFR based on
140	cognitive status, where the variation in AD biomarker levels was significant only in the MCI group.
141	However, in the NC group the variation with eGFR did not reach statistical significance. (Table 3) This
142	observation indicates that the impact of eGFR on AD biomarker levels is more pronounced in individuals
143	with cognitive impairment. (Figure 1)
144	Finally, after adjusting for hypertension and diabetes, which was available only for a subsample (N=375,
145	50.74% with hypertension and 12.76% with diabetes), the association between the A β 42/Tau ratio, Tau,

148 **Discussion:**

In our present study of a large cohort of older adults with CSF biomarker quantifications, we found 149 150 kidney function was associated with the levels of AD biomarkers in the CSF. Although these associations 151 remained significant after adjusting for cognitive status, we observed significant interactions between 152 MCI and eGFR where the impact of this association is more pronounced in individuals with MCI. The significant association between CSF biomarkers and both eGFR and MCI, even after adjusting for 153 154 confounders reinforces the notion from previous studies of a more direct influence of kidney health on 155 AD-related pathology.¹⁹ Earlier studies have consistently indicated a link between kidney function, cognitive impairment, and dementia.¹⁰⁻¹³ Additionally recent studies have found that the kidneys play a 156 physiological role in the clearance of A β from the blood and brain in both humans and animals,^{20,21} as 157 well as Tau having a physiological role in the kidneys.²² Furthermore, studies have suggested that Aβ 158 from the periphery might be contributing to AD pathogenesis by increasing the levels of A β crossing the 159 blood brain barrier (BBB) and inducing A β -related pathologies in the brain.^{23,24} Therefore, given it has 160 been established that lower Aβ42 levels in the CSF or plasma are associated with increased amyloid 161 deposition in the brain by many clinical studies ^{23,25-29} and the amyloid hypothesis that suggests AD is 162 due to the imbalance of $A\beta$,³⁰ a possible explanation for our findings is the decline in kidney function 163 resulted in decreased clearance and therefore accumulation of AD pathology.^{31,32} Another possible 164 165 explanation is that the decline in kidney function contributed to an increase in production of AD 166 biomarkers in the brain. In both scenarios, the association of kidney function with AD biomarkers needs further exploration. It is also worth noting that the associations between kidney function and Tau and 167 168 Aβ42/tau ratio were significant after adjusting for hypertension and diabetes, suggesting that our findings 169 are independent of common risk factors for kidney function loss. Our finding that adjusting for hypertension and diabetes renders the Aβ42-kidney function association not significant may imply that it 170 171 is related to kidney disease risk factors. This supports previous studies that demonstrated an association 172 between increased plasma levels of A β and vascular disease in both the brain and the periphery including

- hypertension, and diabetes.²⁴ However, it is important to note that this analysis was only conducted on a
 subsample and hence need to be interpreted with caution.
- 175 This is to our knowledge one of the few first large studies that reported the association of kidney function
- 176 with CSF AD biomarkers and its interaction with cognitive status. This study highlights the need to
- 177 incorporate kidney function in studies of AD risk factors and the need to consider renal health when
- 178 interpreting the results of AD biomarkers^{33,34} within clinical evaluations and trials particularly during the
- 179 early symptomatic stages of AD. This also adds an additional factor to our understanding of the complex
- 180 multifactorial processes contributing to AD and its biomarkers.

181 Limitations:

182 This study has a few limitations that are related to the cross-sectional nature of this analysis. Nevertheless,

the observation of an association between kidney function and AD biomarkers cross-sectionally is

184 significant. However, considering that the AD biomarkers were measured at a single point, whether

185 kidney function would influence these measures in a longitudinal study remains an important and

186 unexplored phenomenon.

187 Future Directions:

188 It is important that future studies investigate the association with other known comorbidities such as

189 microvascular dysfunction, vitamin D metabolism, erythropoietin variation, and alterations in the renin-

190 angiotensin system and their effects on AD biomarker variations. Studying their effects on AD biomarker

191 variations could offer insights into the mechanisms for increased risk of AD in high-risk populations such

as older adults, African Americans (AA) or those with Diabetes and hypertension.

193 Conclusion:

In conclusion, our study provided insights into the complex association between kidney function, AD
biomarkers, and cognitive impairment. The findings suggest a significant association between kidney

function and variation in levels of AD biomarkers in the CSF (A β 42, tau, and pTau), w	which were stronger
---	---------------------

- in individuals with MCI. This suggests that kidney function should be considered in the context of
- 198 interpreting AD biomarkers in clinical evaluations and clinical trials, especially in those in the early
- 199 symptomatic stage of AD. Future studies need to further explore the impact of kidney function and other
- 200 comorbidities on the interpretation of AD Biomarkers.

201 Acknowledgements:

- 202 Corresponding Author: Ihab Hajjar, MD, Department of Neurology, University of Texas Southwestern
- 203 Medical Center, 5323 Harry Hines Blvd, 4th floor, Dallas, TX 75390-8806, USA. Email:
- 204 Ihab.Hajjar@UTSouthwestern.edu
- 205 Author Contributions: Dr Hajjar had full access to all of the data in the study and takes responsibility
- for the integrity of the data and the accuracy of the data analysis.
- 207 Concept and design: Hajjar.
- 208 Acquisition, analysis, or interpretation of data: Hajjar
- 209 *Drafting of the manuscript:* Hajjar, Neal, Yang.
- 210 *Critical revision of the manuscript for important intellectual content:* All authors.
- 211 *Statistical analysis:* Hajjar, Yang.
- 212 Administrative, technical, or material support: Hajjar
- 213 Conflict of Interest Disclosures: None reported.
- **Funding/Support:** This study was funded by the National Institute on Aging (NIA)
- 215 Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study;
- collection, management, analysis, and interpretation of the data; preparation, review, or approval of the
- 217 manuscript; and decision to submit the manuscript for publication.

218 References:

219

220	1.	Papaliagkas V	, Kalinderi K.	Vareltzis P.	Moraitou D.	Papamitsou T	, Chatzidimitriou M. CS	SF
		A			,		,	

221 Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease. *International*

- *Journal of Molecular Sciences*. 2023;24(10):8976.
- 223 2. Bouwman FH, Schoonenboom NS, Verwey NA, et al. CSF biomarker levels in early and late
- onset Alzheimer's disease. *Neurobiology of aging*. 2009;30(12):1895-1901.

225 3. Hampel H, Teipel SJ, Fuchsberger T, et al. Value of CSF β -amyloid1–42 and tau as predictors of

Alzheimer's disease in patients with mild cognitive impairment. Molecular psychiatry. 2004;9(7):705-

227 710.

4. Jack Jr C, Bennett D, Blennow K, et al. NIA-AA research framework: toward a biological

definition of Alzheimer's disease. Alzheimers Dement 14 (4): 535–562. 2018.

230 5. Mattsson N, Insel PS, Donohue M, et al. Predicting reduction of cerebrospinal fluid β-amyloid 42

in cognitively healthy controls. *Jama neurology*. 2015;72(5):554-560.

6. Garrett SL, McDaniel D, Obideen M, et al. Racial disparity in cerebrospinal fluid amyloid and tau

biomarkers and associated cutoffs for mild cognitive impairment. JAMA network open.

234 2019;2(12):e1917363-e1917363.

7. Morris JC, Schindler SE, McCue LM, et al. Assessment of racial disparities in biomarkers for
Alzheimer disease. *JAMA neurology*. 2019;76(3):264-273.

8. Sundermann EE, Panizzon MS, Chen X, et al. Sex differences in Alzheimer's-related Tau

biomarkers and a mediating effect of testosterone. *Biology of sex Differences*. 2020;11:1-10.

239 9. Yang J, Brody EN, Murthy AC, et al. Impact of kidney function on the blood proteome and on

240 protein cardiovascular risk biomarkers in patients with stable coronary heart disease. Journal of the

241 American Heart Association. 2020;9(15):e016463.

- 242 10. Basit S, Damholt MB, Wohlfahrt J, Boyd HA. Is kidney disease associated with both Alzheimer's
- 243 disease and vascular dementia? Epidemiology/Risk and protective factors in MCI and dementia.

244 *Alzheimer's & Dementia*. 2020;16:e042527.

- 245 11. Xu H, Garcia-Ptacek S, Trevisan M, et al. Kidney function, kidney function decline, and the risk
- of dementia in older adults: a registry-based study. *Neurology*. 2021;96(24):e2956-e2965.
- 247 12. Zhang C-Y, He F-F, Su H, Zhang C, Meng X-F. Association between chronic kidney disease and
- Alzheimer's disease: An update. *Metabolic Brain Disease*. 2020;35:883-894.
- 249 13. Singh-Manoux A, Oumarou-Ibrahim A, Machado-Fragua MD, et al. Association between kidney
- function and incidence of dementia: 10-year follow-up of the Whitehall II cohort study. *Age and ageing*.
- **251** 2022;51(1):afab259.
- 252 14. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Qualification of the analytical and clinical
- performance of CSF biomarker analyses in ADNI. *Acta neuropathologica*. 2011;121:597-609.
- 254 15. Sun H-L, Yao X-Q, Lei L, et al. Associations of Blood and Cerebrospinal Fluid Aβ and tau Levels
- with Renal Function. *Molecular Neurobiology*. 2023:1-9.
- 256 16. Xie Z, Tong S, Chu X, Feng T, Geng M. Chronic kidney disease and cognitive impairment: The
- kidney-brain axis. *Kidney Diseases*. 2022;8(4):275-285.
- 258 17. Levey AS. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): a new equation to
- estimate glomerular filtration rate. *Ann Intern Med.* 2009;150:604-612.
- 260 18. Sheu C-F, Suzuki S. Meta-analysis using linear mixed models. *Behavior Research Methods*,
- 261 Instruments, & Computers. 2001;33(2):102-107.
- 262 19. Shi Y, Liu Z, Shen Y, Zhu H. A novel perspective linkage between kidney function and
- Alzheimer's disease. *Frontiers in cellular neuroscience*. 2018;12:384.
- 264 20. Ghiso J, Calero M, Matsubara E, et al. Alzheimer's soluble amyloid β is a normal component of
- 265 human urine. *FEBS letters*. 1997;408(1):105-108.
- 266 21. Tian D-Y, Cheng Y, Zhuang Z-Q, et al. Physiological clearance of amyloid-beta by the kidney and
- its therapeutic potential for Alzheimer's disease. *Molecular Psychiatry*. 2021;26(10):6074-6082.

268	22.	Vallés-Saiz L, Peinado-Cahuchola R, Ávila J, Hernández F. Microtubule-associated protein tau in
269	murin	e kidney: role in podocyte architecture. Cellular and Molecular Life Sciences. 2022;79(2):97.
270	23.	Bu X, Xiang Y, Jin W, et al. Blood-derived amyloid-β protein induces Alzheimer's disease
271	patho	logies. Molecular psychiatry. 2018;23(9):1948-1956.
272	24.	Janelidze S, Stomrud E, Palmqvist S, et al. Plasma β -amyloid in Alzheimer's disease and vascular
273	diseas	se. Scientific reports. 2016;6(1):26801.
274	25.	Grimmer T, Riemenschneider M, Förstl H, et al. Beta amyloid in Alzheimer's disease: increased
275	depos	ition in brain is reflected in reduced concentration in cerebrospinal fluid. Biological psychiatry.
276	2009;	65(11):927-934.
277	26.	Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS β -amyloid in
278	Alzhe	imer's disease. Science. 2010;330(6012):1774-1774.
279	27.	Palmqvist S, Mattsson N, Hansson O, Initiative AsDN. Cerebrospinal fluid analysis detects
280	cereb	ral amyloid- β accumulation earlier than positron emission tomography. <i>Brain</i> . 2016;139(4):1226-
281	1236.	
282	28.	Strozyk D, Blennow K, White L, Launer L. CSF A β 42 levels correlate with amyloid-
283	neuro	pathology in a population-based autopsy study. Neurology. 2003;60(4):652-656.
284	29.	Tapiola T, Alafuzoff I, Herukka S-K, et al. Cerebrospinal fluid β -amyloid 42 and tau proteins as
285	bioma	arkers of Alzheimer-type pathologic changes in the brain. Archives of neurology. 2009;66(3):382-
286	389.	
287	30.	Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on
288	the ro	ad to therapeutics. science. 2002;297(5580):353-356.
289	31.	Kelly DM, Rothwell PM. Disentangling the relationship between chronic kidney disease and
290	cogni	tive disorders. Frontiers in Neurology. 2022;13:830064.
291	32.	Wang Y-J, Zhou H-D, Zhou X-F. Clearance of amyloid-beta in Alzheimer's disease: progress,
292	proble	ems and perspectives. Drug discovery today. 2006;11(19-20):931-938.

- 293 33. Stocker H, Beyer L, Trares K, et al. Association of kidney function with development of
- 294 Alzheimer disease and other dementias and dementia-related blood biomarkers. JAMA Network Open.
- 295 2023;6(1):e2252387-e2252387.
- 296 34. Syrjanen JA, Campbell MR, Algeciras-Schimnich A, et al. Associations of amyloid and
- 297 neurodegeneration plasma biomarkers with comorbidities. *Alzheimer's & Dementia*. 2022;18(6):1128-
- **298** 1140.
- 299
- 300
- 301

Characteristic		Combined sample	NC	MCI	<i>P</i> -value ^b
Ν		973	560 (57.6%)	413 (42.4%)	
Age, years me	ean (SD)	66.52 (8.83)	64.7 ± 8.3	69.0 ± 8.9	< 0.001*
Sov (9/)	Female	613 (63%)	383(68.4%)	230(55.7%)	< 0.001*
Sex (70)	Male	360 (37%)	177(31.6%)	183(44.3%)	
$\mathbf{D}_{2222}(0/1)$	AA	227 (23.33)	114(20.4%)	113(27.4%)	0.011*
Race (%)	White	746 (76.67%)	446(79.6%)	300(72.6%)	
eGFR mean (SD)		78.00 (16.70)	79.2 (15.9)	76.3 (17.6)	0.007*
Aβ42, pg/ml: mean (SD)		385.15 (178.22)	457.2 (184.1)	287.5 (111)	<0.001*
Tau, pg/ml mean (SD)		66.75 (43.29)	51.3 (23.4)	87.6 (53.9)	< 0.001*
pTau pg/ml mean (SD)		31.52 (22.08)	24.9 (11.9)	40.6 (28.6)	< 0.001*
Aβ42/tau Ratio mean (SD)		8.06 (6.09)	10.7 (6.4)	4.5 (3.1)	<0.001*

Table 1: Descri	ptive charact	teristics of th	e pooled	sample ^a
	-			

^b *P*-values obtained through a pooled analysis using t-test for continuous data, and chi-square for discrete data.

^a **Abbreviations**: - **NC**: Normal Cognition, **MCI**: Mild Cognitive Impairment, **SD**: standard deviation, **N**: Sample size, **eGFR**: Estimated Glomerular Filtration Rate, **Aβ42**: Amyloid-β42, **Tau**: Tau protein, **pTau**: Phosphorylated Tau protein, **AA**: African American.

Biomarker	Change ^c per unit of eGFR (95% CI)	<i>P</i> -value	MCI adjusted Change ^d per unit of eGFR (95% CI)	<i>P</i> - value
Aβ42 pg/ml	0.75, (0.27,1.23)	0.002	0.52 (0.03, 1.01)	0.04
Tau pg/ml	-0.39, (-0.55, -0.23)	< 0.001	-0.23 (-0.38, -0.09)	0.001
pTau pg/ml	-0.13, (-0.19, -0.06)	0.0002	-0.07 (-0.14, -0.01)	0.02
Aβ42/Tau Ratio	0.033, (0.02,0.05)	< 0.001	0.03 (0.01, 0.04)	0.002

 Table 2: Association of CSF biomarkers with estimated Glomerular filtration rate from the pooled sample^{ab}

^a Abbreviations: CI 95%: 95% Confidence Interval, eGFR: Estimated Glomerular Filtration Rate, MCI: Mild Cognitive Impairment, Aβ42: Amyloid-β42, Tau: Tau protein, pTau: Phosphorylated Tau protein.

^b *P*-values were obtained through a meta-analysis using linear mixed-effects models and 'Study' as a random effect.

^c Change is the Beta coefficient for the change in the CSF biomarker Levels per change in eGFR.

^d Change is the Beta coefficient for the change in the CSF biomarker Levels per change in eGFR adjusted for MCI

Biomarkers	Effects	β	CI 95%	P-value ^c
Aβ42 pg/ml	eGFR * MCI	1.37	(0.4, 2.33)	0.005
Tau pg/ml	eGFR * MCI	-0.30	(-0.59, -0.01)	0.04
pTau pg/ml	eGFR * MCI	-0.13	(-0.25, 0)	0.05
Aβ42/Tau Ratio	eGFR * MCI	0.03	(0, 0.06)	0.05

Table 3: Interaction between MCI, CSF biomarkers, and eGFR from the pooled sample ^{ab}

^b Model includes the interaction term eGFR*MCI and uses Study as a random effect.

^c *P*-values obtained through Meta-analysis of the data from both studies (BSHARP & CRIN).

^a Abbreviations: β: Beta coefficient for interaction between CSF biomarkers, CI 95%: 95% Confidence Interval, MCI: Mild Cognitive Impairment, eGFR: Estimated Glomerular Filtration Rate, Aβ42: Amyloid-β42, Tau: Tau protein, pTau: Phosphorylated Tau protein.



Figure 1. Impact of MCI on the Association Between CSF AD-Biomarker levels and eGFR

Interaction analysis performed using linear mixed models to assess differences in the relationship between cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarker levels: (A) A β 42, (B) Tau, (C) pTau, and (D) A β 42/Tau Ratio and estimated glomerular filtration rate (eGFR) based on Cognitive status. The slope and intercept are plotted separately for individuals with Mild Cognitive Impairment (MCI) and those with Normal Cognition (NC). The p-value presented is for the interaction term (eGFR*MCI), it suggests a significant difference in the association between these variables based on cognitive status.